Kymera Therapeutics, Inc.
KYMR
$25.97
$0.953.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -52.32% | -0.01% | -0.16% | 2.80% | 5.07% |
| Total Depreciation and Amortization | 106.82% | 79.75% | 54.13% | 30.86% | 19.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.29% | 24.23% | 26.87% | 23.38% | 4.18% |
| Change in Net Operating Assets | -993.74% | 62.45% | 106.93% | 123.01% | 107.13% |
| Cash from Operations | -89.16% | 17.11% | 30.65% | 37.20% | 32.83% |
| Capital Expenditure | 62.77% | -1.29% | -93.91% | -495.21% | -1,115.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -324.38% | -555.22% | -1,872.39% | -793.01% | 646.59% |
| Cash from Investing | -388.86% | -736.60% | -781.24% | -1,219.05% | 581.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,973.68% | 72.59% | 95.47% | 96.73% | 93.27% |
| Issuance of Common Stock | 14,866.96% | 10,927.33% | 128.56% | 129.97% | -97.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 14,424.12% | 14,338.85% | 130.38% | 131.72% | -97.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.10% | 139.58% | 161.46% | 161.53% | 101.89% |